Discovery of ITX 4520: A highly potent orally bioavailable hepatitis C virus entry inhibitor

被引：19

作者：

Mittapalli, Gopi Kumar ^{[1
]}

Zhao, Fang ^{[1
]}

Jackson, Andrew ^{[1
]}

Gao, Hongfeng ^{[1
]}

Lee, Haekyung ^{[1
]}

Chow, Stephine ^{[1
]}

Kaur, Maninder Pal ^{[1
]}

Natalie Nguyen ^{[1
]}

Zamboni, Robert ^{[1
]}

McKelvy, Jeffrey ^{[1
]}

Wong-Staal, Flossie ^{[1
]}

Macdonald, James E. ^{[1
]}

机构：

[1] iTherX Pharmaceut Inc, San Diego, CA 92191 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2012年 / 22卷 / 15期

关键词：

Hepatitis C virus; Entry inhibitors; Bioisostere; Oral bioavailability; Scavenger receptor B-1; HCV ENTRY; INFECTION; RECEPTOR; CULTURE; DRUGS;

D O I：

10.1016/j.bmcl.2012.06.038

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The manuscript reports an identification of a highly potent, orally bioavailable hepatitis C virus entry inhibitor through optimization of a previously reported class of molecules (1) that were not stable in the rat plasma. Compound 39 (ITX 4520) exhibited an excellent PK profile in both rats and dogs with good oral exposure, half-life and oral bioavailability. The compound is also well-tolerated in the preliminary in vivo toxicity studies and has been selected as a pre-clinical candidate for our HCV clinical pipeline. (c) 2012 Elsevier Ltd. All rights reserved.

引用

页码：4955 / 4961

页数：7

共 50 条

[41] Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor
Ito, Toshiya
Kinoshita, Kazutomo
Tomizawa, Masaki
Shinohara, Shojiro
Nishii, Hiroki
Matsushita, Masayuki
Hattori, Kazuo
Kohchi, Yasunori
Kohchi, Masami
Hayase, Tadakatsu
Watanabe, Fumio
Hasegawa, Kiyoshi
Tanaka, Hiroshi
Kuramoto, Shino
Takanashi, Kenji
Oikawa, Nobuhiro
JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (18) : 12427 - 12444
[42] PRECLINICAL CHARACTERIZATION OF THE NOVEL, ORALLY BIOAVAILABLE HEPATITIS B VIRAL ENTRY INHIBITOR A2342
Lindstrom, Erik
Gillberg, Per-Goran
Uzelac, Ivana
Starke, Ingemar
Bonn, Britta
Strangberg, Ellen
Mattsson, Jan
Akerblad, Peter
Pal, Runa
Gaur, Ashwani
Kangarajan, Ramesh
Singh, Shivendra
Kulkarni, Santosh
Truong, Jennifer
Rao, Anuradha
Dawson, Paul A.
HEPATOLOGY, 2021, 74 : 512A - 513A
[43] Discovery of selective, orally bioavailable inhibitor of mouse chitotriosidase
Mazur, Marzena
Bartoszewicz, Agnieszka
Dymek, Barbara
Salamon, Magdalena
Andryianau, Gleb
Kowalski, Michal
Olejniczak, Sylwia
Matyszewski, Krzysztof
Pluta, Elzbieta
Borek, Bartlomiej
Stefaniak, Filip
Zagozdzon, Agnieszka
Mazurkiewicz, Marcin
Koralewski, Robert
Czestkowski, Wojciech
Piotrowicz, Michal
Niedziejko, Piotr
Gruza, Mariusz M.
Dzwonek, Karolina
Golebiowski, Adam
Golab, Jakub
Olczak, Jacek
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (03) : 310 - 314
[44] Phosphorothioate oligonucleotide is a potent entry inhibitor of hepatitis C virus infection in vitro and in vivo
Matsumura, Takuya
Kato, Takanobu
Hu, Zongyi
Imamura, Michio
Hiraga, Nobuhiko
Juteau, Jean-Marc
Vaillant, Andrew
Chayama, Kazuaki
Liang, T. Jake
HEPATOLOGY, 2007, 46 (04) : 852A - 852A
[45] Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease
Perni, RB
Almquist, SJ
Byrn, RA
Chandorkar, G
Chaturvedi, PR
Courtney, LF
Decker, CJ
Dinehart, K
Gates, CA
Harbeson, SL
Heiser, A
Kalkeri, G
Kolaczkowski, E
Lin, K
Luong, YP
Rao, BG
Taylor, WP
Thomson, JA
Tung, RD
Wei, YY
Kwong, AD
Lin, C
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) : 899 - 909
[46] Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor
Tang, Kai
Wang, Shu
Feng, Siqi
Yang, Xinyu
Guo, Yueyang
Ren, Xiangli
Bai, Linyue
Yu, Bin
Liu, Hong-Min
Song, Yihui
ACTA PHARMACEUTICA SINICA B, 2024, 14 (08) : 3624 - 3642
[47] Novel, potent and orally bioavailable indolizidinone-derived inhibitors of the hepatitis C virus NS3 protease
Clarke, Michael O.
Byun, Daniel
Chen, Xiaowu
Doerffler, Edward
Leavitt, Stephanie A.
Sheng, X. Christopher
Yang, Cheng Y.
Kim, Choung U.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (02) : 1095 - 1098
[48] Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor
Lal, Shruti
Bhola, Neil E.
Sun, Bee-Chun
Chen, Yuping
Huang, Tom
Morton, Vivian
Chen, Kevin X.
Xia, Shanghua
Zhang, Haoyu
Parikh, Nehal S.
Ye, Qiuping
Veiby, O. Petter
Bellovin, David I.
Ji, Yuhua
CANCER RESEARCH COMMUNICATIONS, 2023, 3 (09): : 1731 - 1742
[49] DISCOVERY OF POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS (HCV) ENTRY WITH DISTINCT MECHANISMS OF ACTION
Coburn, G. A.
Han, A. Q.
Murga, J. D.
de Muys, J. -M.
Fisch, D. N.
Paul, D.
Moorji, S.
Provoncha, K. P.
Rotshteyn, Y.
Qian, D.
Maddon, P. J.
Olson, W. C.
JOURNAL OF HEPATOLOGY, 2010, 52 : S50 - S50
[50] Next generation oral anticoagulant: The discovery of Apixaban, a potent, selective, and orally bioavailable factor Xa inhibitor
Lam, Patrick Y. S.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242

← 1 2 3 4 5 →